Supplementary materials for the article:

Rahim M.A. et al. A Clinical Trial to Evaluate the Efficacy of α-Viniferin in *Staphylococcus aureus* – Specific Decolonization without Depleting the Normal Microbiota of Nares
Pol J Microbiol. 2021, Vol. 70, No 1, 117–130.

Table SI
The characteristics of the subjects enrolled in clinical trial.

No.	ID	Age	Gender
1	4689	23	Female
2	4871	24	Female
3	4872	27	Female
4	3369	37	Female
5	3656	40	Female
6	2895	42	Female
7	3591	43	Female
8	4671	46	Female
9	2931	46	Female
10	4823	47	Female
11	1854	47	Female
12	3916	48	Female
13	4648	48	Female
14	3169	48	Female
15	2623	49	Female
16	3853	50	Female
17	3341	50	Female
18	4007	51	Female
19	4854	51	Female
20	3854	56	Female

Table SII
The characteristics of the subjects participated in skin irritation test.

Items	Classification	Frequency (n)	Percentage (%)
Age	20’s	5	15.63
	30’s	1	3.13
	40’s	26	81.24
	50’s	0	0.00
Skin type	Dry	14	43.74
	Normal	7	21.88
	Oily	0	0.00
	Combination	11	34.38
	Troubled skin	0	0.00

Skin moisture	Moist	0	0.00
	Normal	17	53.12
	Dry	12	37.50
	Extremely dry	3	9.38
Skin sebum	Glossy	0	0.00
	Normal	28	87.50
	Deficient	4	12.50
Body dryness	Moist	0	0.00
	Normal	16	50.00
	Dry	14	43.75
	Extremely dry	2	6.25
Number of showers (1week)	Less than 1-time	1	3.13
	2 ~ 3-time	8	25.00
	4 ~ 6-time	10	31.24
	Once a day	12	37.50
	More than twice a day	1	3.13
Using Body Products	Do not used	5	15.63
	Occasionally used	16	50.00
	Always used	11	34.37
UV exposure (daily)	Less than 1hr	12	37.50
	1 ~ 3 hrs.	19	59.37
	More than 3 hrs.	1	3.13
Sleep (daily)	Less than 5 hrs.	1	3.13
	5 ~ 8 hrs.	30	93.74
	More than 8 hrs.	1	3.13
Smoking (daily)	No	32	100.00
Sensitive skin	Yes	2	6.25
	No	30	93.75
After applying personal products	Yes	0	0.00
	No	32	100.00
Experience of adverse reaction to α-viniferin	Yes	0	0.00
	No	32	100.00
Change of skin during of women period	Yes	5	15.63
	No	26	81.24
	N/A	1	3.13
The current state	A week before women period	13	40.63
	Having a women period	5	15.62
	In a week after women period	5	15.62
	Etc.	9	28.13
	N/A	0	0.00



Fig. S1. Agarose Gel Electrophoresis. Total RNA from was extracted from α-viniferin-treated broth cultures of *S. aureus* at different conditions, including drug-free, 1 × MIC, and 2 × MIC, according to the manufacturer's instructions. Then it was visualized on the 2% agarose gel using ethidium bromide. The experiment was done in duplicate.

Table SIII

Determination of the MIC of α-viniferin and two control drugs against 20 bacterial strains.

Strain SL No.	Bacterial strain name	NCCP No.	MIC (in μg/ml)		
			α-Viniferin	VAN	MET
1	*Escherichia coli*	14762	> 250	18.8	> 150
2	*Proteus vulgaris*	14765	> 250	> 150	37.5
3	*Shigella boydii*	14745	> 250	4.8	> 150
4	*Shigella flexneri*	14744	> 250	> 150	> 150
5	*Shigella dysenteriae*	14746	> 250	> 150	> 150
6	*Staphylococcus aureus*, MSSA	14780	7.8	0.6	2.4
7	*Staphylococcus epidermidis*, MRSE	14768	7.8	1.2	75
8	*Staphylococcus aureus*, MRSA	14769	7.8	0.6	> 150
9	*Corynebacterium diphtheria*	10353	> 250	0.6	4.8
10	*Salmonella enteritidis*	14771	> 250	> 150	> 150
11	*Acinetobacter baumannii*	14782	> 250	37.5	9.6
12	*Streptococcus sanguis*	14775	> 250	0.3	1.2
13	*Streptococcus pyogenes*	14783	> 250	0.1	0.6
14	*Streptococcus pneumoniae*	14774	> 250	0.3	2.4
15	*Serratia marcescens*	14770	> 250	> 150	> 150
16	*Citrobacter freundii*	14766	> 250	> 150	> 150
17	*Enterobacter aerogenes*	14761	> 250	> 150	> 150
18	*Proteus mirabilis*	14763	> 250	> 150	75
19	*Klebsiella pneumoniae*	14764	> 250	> 150	> 150
20	*Escherichia coli* O157	14541	> 250	37.5	> 150

VAN – vancomycin; MET – methicillin; MSSA – methicillin-susceptible *Staphylococcus aureus*; MRSE – methicillin-resistant *Staphylococcus epidermidis*; MRSA – methicillin-resistant *Staphylococcus aureus*; NCCP – National Culture Collection of Pathogens